Activity‐based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights

Abstract

The reversible post-translational modification of proteins by ubiquitin and ubiquitin-like proteins regulates almost all cellular processes, by affecting protein degradation, localization, and complex formation. Deubiquitinases (DUBs) are proteases that remove ubiquitin modifications or cleave ubiquitin chains. Most DUBs are cysteine proteases, which makes them well suited for study by activity-based probes. These DUB probes report on deubiquitinase activity by reacting covalently with the active site in an enzyme-catalyzed manner. They have proven to be important tools to study DUB selectivity and proteolytic activity in different settings, to identify novel DUBs, and to characterize deubiquitinase inhibitors. Inspired by the efficacy of activity-based probes for DUBs, several groups have recently reported probes for the ubiquitin conjugation machinery (E1, E2, and E3 enzymes). Many of these enzymes, while not proteases, also posses active site cysteine residues and can be targeted by covalent probes. In this review, we will discuss how features of the probe (cysteine-reactive group, recognition element, and reporter tag) affect reactivity and suitability for certain experimental applications. We will also review the diverse applications of the current probes, and discuss the need for new probe types to study emerging aspects of ubiquitin biology.Abbreviations ABP, activity-based probe; ABPP, activity-based protein profiling; AOMK, acyloxymethyl ketone; Dha, dehydroalanine; DUB, deubiquitinase; HECT, homologous to the E6-AP carboxyl terminus; MS, mass spectrometry; NEDD8, neural precursor cell expressed, developmentally down-regulated 8; OTU, ovarian tumor domain protease; RBR, RING-between-RING; RING, really interesting new

Protein Degradation Systems as Antimalarial Therapeutic Targets

“…The P. falciparum homolog PfUSP14 (PF3D7_0527200) was shown to bind plasmodial proteasomes, and small-molecule inhibition (b-AP15) of this enzyme led to accumulation of proteasomal substrates and P. falciparum death [31]. Inhibitors of the human USP14 are currently in clinical trials to treat multiple myeloma [55, 56]. Recently, multiple natural and synthetic compounds have been identified to inhibit the deubiquitinating activity of the 19S subunit Rpn11 [57–59].…”

Profiling DUBs and Ubl-specific proteases with activity-based probes

“…In addition, their activity may be controlled by posttranslational modifications, such as acetylation, phosphorylation, ubiquitination, or methylation. In order to study the role of DUBs in biological processes, it is therefore insufficient to simply monitor the enzyme's abundance by antibody staining, proteomics, or mRNA quantification because this is not necessarily related to a protein's activity (Hewings, Flygare, Bogyo, & Wertz, 2017). A powerful method to visualize enzyme activities in a complex biological setting is the use of Activity-Based Probes (ABPs) (Ovaa, 2007;Verdoes & Verhelst, 2016).…”

Ubiquitin specific peptidase 49 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling

“…Targeting the ubiquitin‐proteasome pathway (UPP) has been an attractive strategy for anti‐cancer drug discovery since the successful application of bortezomib in the treatment of multiple myeloma in clinic . The UPP at least contains five components, including ubiquitin‐activating enzyme E1, ubiquitin‐conjugating enzyme E2, ubiquitin ligase E3, deubiquitinating enzyme DUB, and the proteasome . Among these, targeting the DUBs has attracted more and more attention from researchers in drug discovery …”